Viewing data from:

NEO-SYNALAR

ANDA

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE | A060700 | EUROFARMA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Neo-Synalar (2023)

Total Spending

$248K

Total Claims

262

Beneficiaries

185

Avg Cost/Unit

$15.28

Spending Trend

$185K(2019)→$167K(2020)→$196K(2021)→$254K(2022)→$248K(2023)

YoY Change:+6.0%

5yr CAGR:+6.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.025%;EQ 3.5MG BASE/GM

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.